181 results on '"Cheze, Stephane"'
Search Results
2. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
3. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
4. PB2086: SIMULTANEOUS DIAGNOSIS OF MULTIPLE MYELOMA AND MYELODYSPLASIA: CASE REPORT.
5. P1613: REAL-WORLD USE OF FOSTAMATINIB IN FRANCE. INTERIM RESULTS OF A NATIONAL REGISTRY.
6. Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy
7. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study
8. Long-term follow-up of the STOPAGO study
9. Nausées-vomissements induits par les traitements anti-cancéreux (NVITAC) : quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS
10. The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France
11. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia
12. Platelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents
13. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
14. Vasculitis associated with large granular lymphocyte (LGL) leukemia: Presentation and treatment outcomes of 11 cases
15. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
16. Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
17. An updated list of drugs suspected to be associated with immune thrombocytopenia based on the WHO pharmacovigilance database
18. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program
19. Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia
20. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients
21. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
22. ZAP-70 intron1 DNA methylation status: Determination by pyrosequencing in B chronic lymphocytic leukemia
23. Épidémiologie des syndromes myélodysplasiques (SMD) et des syndromes myélodysplasiques/syndromes myéloprolifératifs (SMD/SMP): Expérience du Registre régional des hémopathies malignes de Basse-Normandie
24. Splenectomy for Primary Immune Thrombocytopenia Revisited at the Era of Thrombopoietin Receptor Agonists: New Insights for an Old Treatment
25. A Retrospective Multicenter Case Study Evaluating the Characteristics, Management and Outcome of Acquired Amegakaryocytic Thrombocytopenia
26. Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial
27. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
28. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
29. Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.
30. Efficacy and Safety of Dapsone in Primary Immune Thrombocytopenia. Results of a Randomized, Placebo-Controlled Multicenter Trial and of a Single-Arm, Emulated Trial in the Prospective, Multicenter Carmen-France Registry
31. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
32. Chronic Lymphocytic Leukemia: Strategies for Optimizing Therapy
33. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM
34. Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study
35. Risk Factors of Neonatal Immune Thrombocytopenia in Pregnant Women Previously Diagnosed with ITP: Results from a French Nationwide Prospective Study
36. Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
37. CL-24 Formation Transfusion des internes, expérience du CHU de Caen
38. Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study
39. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial
40. Rate of Prolonged Response after Stopping Thrombopoietin-Receptor Agonists Treatment in Primary Immune Thrombocytopenia (ITP): Results from a Nationwide Prospective Multicenter Interventional Study (STOPAGO)
41. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial
42. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
43. Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload
44. Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)
45. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis
46. Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes
47. Transport des produits sanguins labiles et sécurité transfusionnelle
48. Vascularite coronaire associée à une leucémie prolymphocytaire T
49. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
50. Eosinophilic fasciitis with paroxysmal nocturnal hemoglobinuria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.